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A B S T R A C T   
There is a growing body of evidence demonstrating the significant involvement of the sigma-1 chaperone protein 
in the modulation of seizures. Several sigma-1 receptor (Sig1R) ligands have been demonstrated to regulate the 
seizure threshold in acute and chronic seizure models. However, the mechanism by which Sig1R modulates the 
excitatory and inhibitory pathways in the brain has not been elucidated. The aim of this study was to compare 
the susceptibility to seizures of wild type (WT) and Sig1R knockout (Sig1R− /− ) mice in intravenous pentyl-
enetetrazol (PTZ) and (+)-bicuculline (BIC) infusion-induced acute seizure and Sig1R antagonist NE-100-induced 
seizure models. To determine possible molecular mechanisms, we used quantitative PCR, Western blotting and 
immunohistochemistry to assess the possible involvement of several seizure-related genes and proteins. Pe-
ripheral tissue contractile response of WT and Sig1R− /− mice was studied in an isolated vasa deferentia model. 
The most important finding was the significantly decreased expression of the R2 subunit of the GABA-B receptor 
in the hippocampus and habenula of Sig1R− /− mice. Our results demonstrated that Sig1R− /− mice have 
decreased thresholds for PTZ- and BIC-induced tonic seizures. In the NE-100-induced seizure model, Sig1R− /−
animals demonstrated lower seizure scores, shorter durations and increased latency times of seizures compared 
to WT mice. Sig1R-independent activities of NE-100 included downregulation of the gene expression of iNOS and 
GABA-A γ2 and inhibition of KCl-induced depolarization in both WT and Sig1R− /− animals. In conclusion, the 
results of this study indicate that the lack of Sig1R resulted in decreased expression of the R2 subunit of the 
GABA-B receptor and increased susceptibility to seizures. Our results confirm that Sig1R is a significant mo-
lecular target for seizure modulation and warrants further investigation for the development of novel anti-seizure 
drugs.   
1. Introduction 
Epilepsy is a chronic neurological disease that is characterized by 
seizures. The seizures could be caused by disturbances at the receptor 
function and neurotransmission levels, metabolic problems in the cen-
tral nervous system or some conditions leading to pathological changes 
in the brain, such as traumatic brain injuries, stroke, status epilepticus or 
infectious diseases (Alyu and Dikmen, 2017). For the treatment of sei-
zures, heterogeneous groups of antiepileptic drugs (AEDs) are used. 
However, a number of patients do not fully respond to currently 
available treatment, and existing AEDs achieve seizure freedom only in 
approximately two-thirds of patients (Perucca et al., 2018). Therefore, 
searching for new possible mechanisms and novel AEDs is highly 
necessary to identify effective treatments for patients with uncontrolled 
seizures. 
The sigma-1 chaperone protein, also known as the sigma-1 receptor 
(Sig1R), in the cell plays a significant role in the modulation of the ac-
tivity of endoplasmic reticulum-residing proteins, as well as nuclear, 
mitochondrial and plasma-membrane proteins, which are in close 
proximity to the endoplasmic reticulum (Mavlyutov et al., 2015; Su 
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et al., 2016). It has been shown that sigma ligands are involved in 
modulation of the seizure threshold, and both anti-convulsive and pro- 
convulsive activity has been observed for both agonists and antago-
nists (Vavers et al., 2017). Our previous data showed that the Sig1R 
antagonist NE-100 demonstrated pro-convulsive activity at a dose of 25 
mg/kg after i.p. administration in a PTZ-induced seizure model, and 
after administration at doses of 50 and 75 mg/kg, NE-100 induced 
convulsions in naïve animals (Vavers et al., 2017). On the other hand, 
positive allosteric modulators of Sig1R clearly demonstrated anti- 
convulsive activity in in vivo seizure models (Guo et al., 2015; 
reviewed in Vavers et al., 2019). Taken together, these findings strongly 
suggest that Sig1R could be used as a novel drug target to treat seizures. 
The mechanism governing how Sig1R can control the balance between 
excitation and inhibition in vivo has not been fully elucidated. The first 
Sig1R knockout (Sig1R− /− ) mice were described in 2003 (Langa et al., 
2003), and to date, no spontaneous seizures have been observed in 
Sig1R− /− mice. 
In several in vitro studies, it has been shown that Sig1R could alter 
neuronal excitability by modulating the function of voltage-gated so-
dium, potassium and calcium channels (Kourrich, 2017). The activation 
of Sig1R has been demonstrated to inhibit glutamate release in rat ce-
rebral cortex nerve endings (Lu et al., 2012). On the other hand, it has 
been shown that endogenous activators and agonists of Sig1R, such as 
pregnenolone sulfate, dehydroepiandrosterone sulfate and (+)-pentaz-
ocine, can increase presynaptic glutamate release in rat hippocampal 
neurons (Meyer et al., 2002; Dong et al., 2007). In addition, pregneno-
lone sulfate and dehydroepiandrosterone sulfate have been demon-
strated to negatively modulate and decrease the activity of the GABA-A 
receptor (Maurice et al., 2001) and thus may increase the sensitivity of 
mice to pentylenetetrazol (PTZ)-induced seizures (Reddy and Kulkarni, 
1998). The lack of Sig1R in Sig1R− /− mice has been associated with 
dysfunction of GABA-A receptor-mediated inhibition in basolateral 
amygdala principal neurons, probably through the reduction of NMDA 
receptor-mediated GABA release (Zhang et al., 2017). A bidirectional 
modulation of Sig1R agonists of NMDA receptor evoked excitatory 
transmission, in which a low dose of Sig1R agonist is excitatory and a 
high dose is inhibitory (Liang and Wang, 1998), suggesting a complex 
mechanism that is responsible for regulating the balance between 
excitation and inhibition by Sig1R. 
To determine the possible mechanisms governing the role of Sig1R in 
the control of seizures, the aim of this study was to compare the seizure 
threshold and behavioral response of WT and Sig1R− /− mice in 
different acute seizure models in vivo. Changes in seizure-related gene 
and protein expression were analyzed using PCR, Western blotting and 
immunohistochemistry techniques. The isolated vasa deferentia model 
was used to test the role of Sig1R in electrical current-induced 
contractility and potassium chloride-induced depolarization. 
2. Materials and methods 
2.1. Animals 
In total, fifty WT (HSD:ICR(CD-1®), ENVIGO, Venray, Netherlands 
(https://www.envigo.com/model/hsd-icr-cd-1-)) and fifty age-matched 
CD-1 background Sig1R− /− (ENVIGO, Bresso, Italy) male mice aged 
22–25 weeks were used in this study. Briefly, CD-1 background Sig1R− / 
− mouse model is a global knockout generated by homologous recom-
bination techniques (Langa et al., 2003). Homologous recombination 
vector pHR53TK was constructed and used to inactivate the mouse 
Sig1R gene (GenBank: AF030199) in mouse embryonic stem cells (Langa 
et al., 2003). Fifteen and ten mice were employed in the PTZ- and BIC- 
induced seizure threshold tests, respectively. Nine mice per group (WT 
control, WT + NE-100, Sig1R− /− control and Sig1R− /− + NE-100) 
were used in the Sig1R antagonist NE-100-induced seizure model. Seven 
mice were used in the isolated vasa deferentia model. Three Wistar male 
rats (12 weeks; RccHan:WIST, ENVIGO, Venray, Netherlands 
(https://www.envigo.com/model/rcchan-wist)) were used for the [3H] 
muscimol binding assay. All animals were housed under standard con-
ditions (21–23 ◦C, 12 h light-dark cycle) with unlimited access to stan-
dard food (Lactamin AB, Mjölby, Sweden) and water in an individually 
ventilated cage housing system (Allentown Inc., Allentown, New Jersey, 
USA). Each cage contained bedding consisting of EcoPure™ Shavings 
wood chips (Datesand, Cheshire, UK), nesting material and a wooden 
block from TAPVEI (TAPVEI, Paekna, Estonia). For enrichment, trans-
parent tinted (red) nontoxic durable polycarbonate Safe Harbor Mouse 
Retreat (Animalab, Poznan, Poland) was used. For the rat cage enrich-
ment, nontoxic durable transparent polycarbonate rat retreats tinted red 
were used. The mice were housed at a density of 3 to 5 mice per standard 
cage (38 × 19 × 13 cm). The rats were housed at a density of 3 rats per 
standard cage (30 × 41 × 23 cm). All studies involving animals were 
reported in accordance with the ARRIVE guidelines (Kilkenny et al., 
2010; McGrath et al., 2010). The experimental procedures were per-
formed in accordance with the guidelines reported in EU Directive 
2010/63/EU and in accordance with local laws and policies; all of the 
procedures were approved by the Latvian Animal Protection Ethics 
Committee of Food and Veterinary Service in Riga, Latvia. All experi-
ments were performed by experienced scientists who were blinded to the 
experimental groups. 
2.2. Intravenous PTZ- and BIC-induced seizure threshold tests 
Chemoconvulsant-induced clonic and tonic seizures were initiated 
by inserting a 27-gauge needle into the tail veins and infusing 1% PTZ 
(Mandhane et al., 2007; Zvejniece et al., 2010) or 0.01% BIC (Meldrum, 
1975; Vavers et al., 2017) at a constant rate of 20 μl/2 s to restrained 
animals. The infusion was halted when forelimb clonus followed by 
tonic seizures of the full body were observed. Minimal doses of PTZ or 
BIC (mg/kg of mouse weight) necessary to induce clonic and tonic sei-
zures were considered as indices of seizure threshold. In BIC-induced 
seizure model one animal from WT control group was excluded from 
the data due to technical problems. 
2.3. Sig1R antagonist NE-100-induced seizure model 
Based on previous results (Vavers et al., 2017), this model was 
chosen to confirm the role of Sig1R in seizure modulation. NE-100- 
induced seizures were studied at a dose of 75 mg/kg, which induced 
seizures in 100% of animals (Vavers et al., 2017). NE-100 was injected 
intraperitoneally (i.p.), and mice were subsequently placed immediately 
in observation chambers (40 × 25 × 15 cm) and video-recorded for 60 
min using a digital HD video camera recorder (Handycam HDR-CX11E, 
Sony Corporation, Tokyo, Japan). The scoring scale for observed 
behavioral responses of animals was adapted from a previously pub-
lished seizure rating scale (Lüttjohann et al., 2009). Behavioral re-
sponses of animals were scored from the video files using the following 
scale: 0, no abnormality; 1, trembling or wobbly gait; 2, tail lifting; 3, 
clonic seizures while lying on belly; 4, tonic seizures while lying on 
belly; 5 clonic-tonic seizures while lying on belly; 6, motionless or 
sleeping; 7, clonic seizures while lying on side; 8, tonic seizures while 
lying on side; 9, clonic-tonic seizures while lying on side; 10, generalized 
seizures with wild jumping and running (Vavers et al., 2017). The 
maximal score was given for each 60-s period. The latency time until the 
first occurrence of seizures induced by NE-100 was also determined from 
the video files. 
2.4. Quantitative PCR 
Brain tissues were collected immediately after the decapitation of 
animals 75 min after i.p. administration of saline or NE-100 at a dose of 
75 mg/kg. Both hemispheres of mouse brains were separated on ice and 
snap-frozen in liquid nitrogen. Brain samples were stored at − 80 ◦C until 
isolation of RNA. Total RNA was isolated from the brain hemisphere 
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using an RNA Mini Kit (Life Technologies, Grand Island, New York, USA) 
according to the manufacturer’s instructions. The extracted RNA was 
dissolved in 50 μl nuclease-free distilled water and stored at − 80 ◦C until 
it was used for analysis. First-strand cDNA was synthesized using a High- 
Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific, 
Waltham, MA, USA) following the manufacturer’s protocol. Quantita-
tive PCR analysis for Sig1R, sigma-2 receptor (Sig2R), glutamate iono-
tropic receptor NMDA type subunit 1, dopamine receptor 1 (D1R), 
dopamine receptor 2 (D2R), inducible nitric oxide synthase (iNOS), 
GABA-Aα5, GABA-Aβ3, GABA-Aγ2, GABA-B R1, GABA-B R2, binding 
immunoglobulin protein (BiP), P2X purinoceptor 1 (P2RX1), ryanodine 
receptor 3 (RyR3), inward rectifier potassium channel (Kcnj) 3 and 
Kcnj9, ionized calcium-binding adapter molecule 1 (Iba1), CD68 protein 
and beta-actin (β-actin) was performed using SYBR® Green Master Mix 
(Life Technologies, Grand Island, New York, USA). The primer se-
quences used in this study are presented in Supplementary Table 1. The 
primers were obtained from Metabion, Germany. The relative expres-
sion levels for each gene were calculated with the ΔΔCt method, 
normalized to the expression of β-actin and compared to the expression 
levels of age-matched WT animals. 
2.5. Western blot analysis 
The brain hemisphere was homogenized using Bead Ruptor (Omni 
International, USA) in urea buffer (4 mM urea, 140 mM Tris, 1% SDS, 10 
mM EDTA, 5 mM MgCl2, 1% IGEPAL, 1 mM AEBSF, 1 μg/mL aprotinin, 
1 μM leupeptin, 1 μM pepstatin A, 1 mM DTT; pH = 7.4). The homog-
enization cycle was set to 30 s, 4 ms, 0.1 Hz. Homogenates were sub-
sequently centrifuged at 10000 xg for 5 min at 4 ◦C and stored at − 80 ◦C 
until use. The protein concentration in the sample was determined by 
the Lowry method (Lowry et al., 1951). Samples (22.5 μg of total pro-
tein) were loaded in the Invitrogen™ Bolt™ 4–12% Bis-Tris Plus Gel 12- 
well (Thermo Fisher Scientific, Waltham, MA, USA). SuperSignal™ 
Molecular Weight Protein Ladder (Thermo Fisher Scientific, Waltham, 
MA, USA) was utilized as a protein size marker. Electrophoresis was 
performed using a MES running buffer (50 mM MES, 50 mM TRIS, 0.1% 
SDS, 1 mM EDTA, pH = 7.24), and the conditions of 145 V, 1.0 A and 
300 W were set on Mini Gel Tank (Thermo Fisher Scientific, Waltham, 
MA, USA). Proteins were transferred using Invitrogen™ iBlot™ 2 
Transfer Stack PVDF membranes (Thermo Fisher Scientific, Waltham, 
MA, USA) on an Invitrogen™ iBlot™ 2 Dry Blotting System (Thermo 
Fisher Scientific, Waltham, MA, USA). After the transfer step, mem-
branes were blocked in 5% BSA for 1 h and incubated with primary anti- 
GABA A receptor gamma 2/GABRG2 antibody (Cat# ab87328, Abcam, 
Cambridge, MA, USA) overnight at 4 ◦C. The following day, membranes 
were washed 6 times with TBS buffer and incubated with secondary 
anti-mouse IgG HRP-linked antibody (Cat# 7076, CST, Danvers, MA, 
USA) for 1 h at room temperature following repeated washing with TBS 
buffer. Images were captured using Immobilon Western Chemilumi-
nescent HRP Substrate (Cat# WBKLS0500, Merck, Burlington, MA, USA) 
with an Azure c400 Visible Fluorescent Western Blot Imaging System 
(Azure Biosystems, Sierra Court, CA, USA). After imaging, membranes 
were blocked in 5% BSA and washed with TBS buffer, and the same 
membranes were used to detect the amount of the R2 subunit of the 
GABA-B receptor. The same protocol was applied to detect the GABA-B 
receptor using an anti-GABA-B receptor 2/GABBR2 antibody [EP2411Y] 
(Cat# ab75838, Abcam, Cambridge, MA, USA) and a secondary anti- 
rabbit IgG HRP-linked antibody (Cat# 7074, CST, Danvers, MA, USA). 
Images were quantified using AzureSpot 2.0 software (Azure Bio-
systems, Sierra Court, CA, USA). 
2.6. [3H]Muscimol binding assay 
Membranes were isolated as described previously (Gould et al., 
1995). Membrane fraction aliquots were thawed and diluted with 50 
mM TRIS-citrate (pH = 7.1, +4 ◦C). The binding assay buffer consisted 
of 160 μl membrane aliquots (the final protein concentration was 30 μg/ 
well), 20 μl of the test compound or deionized water containing DMSO 
for the control (final concentration of DMSO was 1%), and 20 μl [3H] 
muscimol. The final concentration of [3H]muscimol was 2 nM. 
Nonspecific binding was assessed by adding GABA (100 μM). The sam-
ples were incubated for 30 min on ice. The bound and free radioligands 
were separated by rapid filtration under vacuum (Harvester for 96-well 
microplates, Connectorate AG, Dieticon, Switzerland) using Millipore 
GF/B filter paper (Merck Millipore, Billerica, Massachusetts, USA). The 
filters were washed five times with ice cold 25 mM TRIS-citrate (pH =
7.1, +4 ◦C). The samples’ radioactivity was measured with a Wallac 
MicroBeta2 liquid scintillation counter (PerkinElmer, Waltham, Mas-
sachusetts, USA). 
2.7. Immunohistochemistry 
Mice were anaesthetized using i.p. administration of ketamine (200 
mg/kg) and xylazine (15 mg/kg). The depth of anesthesia was moni-
tored by toe pinch. Animals were transcardially perfused at a speed of 3 
ml/min with 0.01 M phosphate-buffered saline (PBS, pH = 7.4) for 5 
min until the blood was completely removed from the tissue. After 
perfusion, brains were carefully dissected and fixed in 4% PFA overnight 
at 4 ◦C. Brains were cryoprotected with a 10–20-30% sucrose gradient 
over 72 h. Coronal sections (20 μm) were cut using a Leica CM1850 
cryostat (Leica Biosystems, Buffalo Grove, IL, United States). 
2.7.1. Cresyl violet staining 
For cresyl violet staining, coronal frozen sections of mouse brain 
were used. Slides with sections on Superfrost Plus microscope slides 
(Thermo Scientific, Waltham, MA, United States) were rinsed in distilled 
water and then incubated with cresyl echt violet (Abcam; Cat# 
ab246817) for 5 min. Sections were quickly rinsed in distilled water, 
dried overnight at 37 ◦C, cleared in xylene and mounted using DPX 
mounting medium (Sigma-Aldrich, St. Louis, MO, United States) and 
finally coverslipped. Images were taken with a Nikon Eclipse TE300 
microscope (Nikon Instruments, Tokyo, Japan). 
2.7.2. Immunoperoxidase and immunofluorescence of free-floating sections 
The staining of free-floating sections was performed based on a 
method described previously (Kadish et al., 2016) with slight modifi-
cations. Free-floating sections were pretreated for 30 min in 85 ◦C so-
dium citrate solution (pH = 6.0), for 15 min in 0.3% H2O2 (to block 
endogenous peroxidase), and for 15 min in 5% BSA (to block nonspecific 
background staining). Between each step, the sections were washed 
three times (5 min each) in TRIS-buffered saline containing Triton™ X- 
100 (TBS-T) and incubated for 16 h in TBS-T with a primary antibody. 
After incubation with primary antibody, sections were washed three 
times (5 min each) in TBS-T. For co-labeling experiments, the last two 
steps were repeated. Sections were subsequently incubated for 2 h at 
room temperature with a corresponding secondary antibody. The sec-
tions were washed three times (5 min each) in TBS-T. The following 
primary antibodies were used in this study: mouse anti-GABA-B R1 
(1:2000, Abcam, Cat# ab55051), rabbit anti-GABA-B R2 (1:500 (for co- 
labeling staining) 1:2000 (for DAB staining), Abcam, Cat# ab75838), 
rabbit anti-GABA-A γ2 (1:1000, Abcam, Cat# ab87328), mouse anti- 
Substance P (1:200, R&D systems, Cat# MAB4375), mouse anti- 
choline acetyltransferase (ChAT, 1:200, Sigma-Aldrich, Cat# 
AMAB91129-25UL). The following secondary antibodies were used in 
this study: goat anti-mouse IgG (H + L) secondary antibody (1:1000, 
Invitrogen Cat# 31800), goat anti-rabbit IgG (H + L) secondary anti-
body (1:1000, Invitrogen Cat# 65–6140), goat anti-rabbit IgG H&L 
Alexa Fluor® 488 (1:200, Abcam, Cat# ab150077), goat anti-mouse IgG 
(H + L) Rhodamine Red-X (1:200, Invitrogen, Cat# R-6393), goat anti- 
mouse Abberior STAR GREEN (1:200, a gift from Abberior Instruments), 
goat anti-rabbit Abberior STAR RED (1:200, a gift from Abberior In-
struments). Biotinylated antibodies were subsequently incubated for 2 h 
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at room temperature with streptavidin (HRP) (1:1000, Abcam Cat# 
ab7403). Again, the sections were washed three times (5 min each) in 
TBS-T and incubated with freshly prepared DAB reagent for 2 min at 
room temperature. DAB-stained sections were mounted on gelatinized 
slides, cleared in xylene, mounted using DPX mounting medium (Sigma- 
Aldrich, St. Louis, MO, United States), coverslipped, and finally photo-
graphed and measured. Fluorescently labeled sections were mounted 
using Abberior Mount solid antifade (a gift from Abberior Instruments). 
2.7.3. Iba1 and GFAP staining 
Immunohistochemistry was performed using a Rabbit Specific HRP/ 
DAB (ABC) Detection IHC Kit (Abcam, Cat# ab64261) following the 
manufacturer’s instructions. Slices were incubated with primary anti- 
Iba1 antibody (1:1000; Abcam, Cat# ab153696) or anti-GFAP anti-
body (1:1000, Abcam, Cat# ab7260) for 16 h at +4 ◦C. The antibodies 
were diluted in PBS containing 3% BSA and 0.3% Triton™ X-100. 
Stained sections were mounted using DPX mounting medium (Sigma- 
Aldrich, St. Louis, MO, United States) and coverslipped. Images were 
taken with a Nikon Eclipse TE300 microscope (Nikon Instruments, 
Tokyo, Japan). 
2.7.4. Image analysis 
Identical brain sections corresponding to identical anatomical 
structures were used for the analysis. The structures were validated 
using Allen Mouse Brain atlas (http://mouse.brain-map.org/static/atla 
s). For each antibody staining experiment, sections from all animals 
were processed in the same staining tray. Negative controls replacing 
the primary antibody with a buffer solution only (TBS-T) were per-
formed. Obtained OD values of corresponding background staining were 
subtracted from the total OD values measured for each brain structure. 
In the quantification experiments, data were collected from 3 mice per 
genotype, each hemisphere was analyzed separately. In the co-labeling 
experiments, at least two mice and three sections per mouse were 
used for analysis. Images were taken with a Nikon Eclipse TE300 mi-
croscope (Nikon Instruments, Tokyo, Japan). Higher resolution images 
for co-labeling were collected using a Leica TCS SP8 confocal micro-
scope (Leica Microsystems GmbH, Wetzlar, Germany) with a 60×-oil 
objective. Staining was quantified using ImageJ software (ImageJ 
v1.52a). Eight-bit images were generated from the pictures and were 
cropped to contain the regions of interest. Means of optical density (OD) 
were used to quantify the staining intensity of GABA-B R1 and R2 and 
GABA-A γ2 in specific brain structures. For optical density (OD) analysis, 
calibration was performed in accordance with the instructions on the 
ImageJ software website (https://imagej.nih.gov/ij/docs/examples/cal 
ibration/). Images for Iba1 and GFAP staining were thresholded to select 
a specific signal over the background, and the stained area for each re-
gion was calculated and employed for statistical analysis. 
2.8. Electrical field stimulation-induced contractions of isolated vasa 
deferentia 
Both vasa deferentia of WT and Sig1R− /− CD-1 mice were excised 
and immersed in a modified ice-cold Krebs-Henseleit buffer solution 
(content in mmol/l: NaCl 118.0, KCl 4.8, CaCl2 2.5, NaHCO3 24.9, 
K2HPO4 1.2, glucose 10.0 and EDTA 0.05, without MgCl2). Cleaned 
whole vas deferens (~10 mm) were mounted in 10-ml organ baths and 
incubated in a modified Krebs-Henseleit buffer solution that was 
maintained at 32 ◦C and bubbled with 95% CO2 and 5% O2 (with the 
slight modifications described by Kennedy and Henderson, 1989). The 
passive tension was fixed at 0.5 g, and the buffer solution in the organ 
bath was changed every 15 min. After a 60-min adaptation period, the 
isolated vasa deferentia were stimulated with an electrical current set at 
0.1 Hz, a pulse duration of 2 ms, and a voltage of 10 V (DMT CS8 
stimulator, Hinnerup, Denmark). Baseline maximal contractility of the 
vas deferens was induced by the addition of 100 mM KCl. Next, the 
electrical stimulation was turned off, and each isolated vasa deferentia 
was washed several times with a modified Krebs-Henseleit buffer solu-
tion. After 30 min, electrical stimulation was resumed under the same 
parameters. When the stimulation produced a stable contraction 
amplitude, cumulative doses of the Sig1R antagonist NE-100 (at con-
centrations ranging from 1 to 10 μM) or barium chloride (at concen-
tration ranging from 1 to 100 μM) were added. After reaching the 
plateau contraction amplitude, 100 mM KCl was added to induce 
maximal contraction. Vas deferens with contraction amplitude below the 
amplitude of 0.05 g at baseline was excluded from the experiment. 
2.9. Chemicals 
PTZ and BIC were purchased from Sigma-Aldrich Co. Louis, MO, 
USA). NE-100 (4-methoxy-3-(2-phenylethoxy)-N,N-dipropylbenzenee-
thanamine hydrochloride) was obtained from Tocris Bioscience (Bristol, 
UK). Physiological saline (0.9%) was purchased from Fresenius Kabi 
(Warszawa, Poland). [3H]Muscimol (S.A. 30.2 Ci/mmol) was obtained 
from BIOTREND Chemikalien GmbH (Köln, Germany). PTZ was 
weighed and dissolved in 0.9% physiological saline to make a 1% PTZ 
solution. BIC was dissolved in DMSO to prepare a 1% stock solution, 
which was subsequently diluted with saline to make a 0.01% BIC solu-
tion. PTZ and BIC solutions were freshly prepared before each experi-
ment. Compounds were dissolved in saline before use. 
2.10. Experimental design and statistical analysis 
2.10.1. Sample size calculations 
Through a power calculation (using G-power software) for a t-test 
(two group comparison) with α = 0.05, a power of 80%, and a stan-
dardized effect size Cohen’s d = 1.2, a total sample size of 10 mice per 
group was deemed to be sufficient. In the BIC-induced seizure model, we 
used 10 mice per group. In the PTZ-induced seizure model, we used 15 
mice per group due to higher variability in this model compared to the 
BIC-induced seizure model. Our sample size of n = 15 would also enable 
smaller differences to be identified with the same statistical power for 
the same significance level. 
In the NE-100-induced seizure model, it was expected that the Sig1R 
antagonist NE-100 could not induce seizures in Sig1R− /− animals. 
Therefore, differences between WT and Sig1R− /− animals were ex-
pected to be highly pronounced. Through a power calculation for a two- 
way ANOVA test (four group comparison) with α = 0.05, a power of 
80%, and a standardized effect size Cohen’s f = 0.7, a total sample size of 
8 mice per group was determined to be sufficient. Since it was previously 
reported that NE-100 at a dose of 75 mg/kg could induce death in some 
animals (Vavers et al., 2017), an additional 1 animal was added to each 
group of NE-100-induced seizure models. Our sample size of n = 9 would 
also enable smaller differences to be identified with the same statistical 
power for the same significance level. 
2.10.2. Statistical data analysis 
The statistical calculations were performed using the GraphPad 
Prism software package (GraphPad Software, Inc., La Jolla, California, 
USA). For two-group comparisons, Student’s t-test or Mann-Whitney U 
test were used for the datasets that were normally or not normally 
distributed, respectively. The Shapiro-Wilk test was used to test the 
distribution of the data. Time and genotype interactions in the NE-100- 
induced seizure model were analyzed by using repeated measures two- 
way ANOVA. Ordinary two-way ANOVA was used for the comparison of 
the WT control, Sig1R− /− control, WT + NE-100 and Sig1R− /− + NE- 
100 groups in the NE-100-induced seizure model. Repeated measures 
two-way ANOVA was used to compare the dose-dependent effect of NE- 
100 and barium chloride between WT and Sig1R− /− mice in an isolated 
vasa deferentia model. A post hoc test was performed if ANOVA indicated 
significant differences. p values less than 0.05 were considered to be 
significant. 
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3. Results 
3.1. Sig1R− /− mice are more prone to PTZ- and BIC-induced tonic 
seizures 
The susceptibility to seizures of WT and Sig1R− /− mice was 
compared in timed intravenous PTZ and BIC infusion-induced acute 
seizure models. The 1% PTZ intravenous infusion induced clonic and 
tonic seizures in WT animals at doses of 33 ± 1 mg/kg and 70 ± 6 mg/ 
kg, respectively (Fig. 1A, B). Compared to WT mice, Sig1R− /− mice 
demonstrated clonic seizures at a dose of 31 ± 1 mg/kg of PTZ (Fig. 1A), 
while tonic seizures were observed at a dose of 50 ± 4 mg/kg of PTZ 
(Fig. 1B). The response of the PTZ-induced clonic seizures did not differ 
between WT and Sig1R− /− animals (Mann-Whitney U test: p = 0.2328; 
Fig. 1A). In Sig1R− /− mice, the PTZ-induced tonic seizure threshold 
was significantly decreased by 28% compared to WT animals (Mann- 
Whitney U test: p = 0.0041; Fig. 1B). BIC-induced clonic and tonic sei-
zures in WT animals were observed at doses of 0.61 ± 0.03 mg/kg and 
1.12 ± 0.09 mg/kg of BIC, respectively (Fig. 2A and B). The response of 
the BIC-induced clonic seizures did not differ between WT and Sig1R− / 
− animals (unpaired t-test: t(17) = 0.8, p = 0.4539; Fig. 2A). Similar to 
the PTZ-induced seizure model, the tonic seizure threshold was signifi-
cantly decreased in Sig1R− /− mice by 22% (0.88 ± 0.04 mg/kg of BIC; 
unpaired t-test: t(17) = 2.6, p = 0.0187) compared to WT mice (Fig. 2B), 
thereby demonstrating that Sig1R− /− mice are more susceptible to 
tonic seizures in both PTZ- and BIC-induced seizure models. 
3.2. Sig1R− /− mice demonstrate decreased severity of seizure in the NE- 
100-induced seizure model 
The responses of WT and Sig1R− /− mice in the NE-100-induced 
seizure model were different and could be divided into two phases. 
Acute seizures of NE-100 (up to 20 min) were observed in both WT and 
Sig1R− /− mice, while the second phase, which started 20–22 min after 
administration of NE-100, was observed only in WT animals (Fig. 3A). 
The average maximal seizure score in WT mice was 7.6 while in Sig1R− / 
− mice it was 5.4 points (Fig. 3A). There was a significant genotype x 
time interaction observed between seizure severities (two-way repeated- 
measures ANOVA: F(59, 944) = 4.3, p < 0.0001 for genotype x time 
interaction; F(1, 16) = 17.4, p = 0.0007 for genotype; F(5, 83) = 19.2, p <
0.0001 for time; Fig. 3A). As demonstrated by the data expressed as the 
areas under the curves (AUCs), the seizure severity after administration 
of NE-100 in Sig1R− /− mice was less pronounced than that in WT an-
imals (Mann-Whitney U test: p = 0.0040; Fig. 3B). Compared to WT 
animals, in which seizures lasted at least 34 min (Fig. 3A, C), the NE- 
100-induced seizures in Sig1R− /− mice lasted for significantly shorter 
lengths of time (Mann-Whitney U test: p = 0.0012; Fig. 3C). One 
Sig1R− /− mouse did not show any signs of seizures after administration 
of NE-100 at a dose of 75 mg/kg (Fig. 3B, C). Sig1R− /− mice exhibited a 
significantly higher latency time to NE-100-induced seizures (Mann- 
Whitney U test: p = 0.0380; Fig. 3D). NE-100-induced clonic seizures in 
Sig1R− /− mice were observed for a significantly shorter time than in 
WT animals (Mann-Whitney U test: p = 0.0199 for clonic seizures while 
lying on the belly; p = 0.0097 for clonic seizures while lying on the side; 
Fig. 4). 
3.3. NE-100-induced seizures result in the downregulation of mRNA 
levels of iNOS and the γ2 subunit of the GABA-A receptor 
Sig1R gene expression was observed only in WT mice, but not in 
Sig1R− /− mice (Table 1). No significant differences in other investi-
gated gene expression levels were found between WT and Sig1R− /−
control mice (Table 1). However, Sig1R− /− animals presented a slight 
tendency of decreased GABA-B R2 mRNA levels (Mann-Whitney U test: 
p = 0.1111; Table 1). The administration of NE-100 induced significant 
downregulation of the gene expression of iNOS (Mann-Whitney U test: p 
= 0.0022) and the γ2 subunit of the GABA-A receptor (Mann-Whitney U 
Fig. 1. Comparison of the response of WT and Sig1R− /− mice in the PTZ- 
induced seizure model. PTZ-induced clonic (A) and tonic (B) seizure thresh-
olds. Data are expressed as the mean ± SEM (n = 15). *p < 0.05 Sig1R− /− mice 
vs WT mice (Mann-Whitney test). 
Fig. 2. Comparison of the response of WT and Sig1R− /− mice in the BIC- 
induced seizure model. BIC-induced clonic (A) and tonic (B) seizure thresh-
olds. Data are expressed as the mean ± SEM (n = 9 WT mice and n = 10 
Sig1R− /− mice). *p < 0.05 Sig1R− /− mice vs WT mice (unpaired t-test). 
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test: p = 0.0303) in WT mice (Table 1). Significant downregulation of 
the gene expression of iNOS (Mann-Whitney U test: p = 0.0159) and the 
γ2 subunit of the GABA-A receptor (Mann-Whitney U test: p = 0.0286) 
was also observed in Sig1R− /− mice after administration of NE-100 
(Table 1). 
3.4. Sig1R− /− mice demonstrate reduced expression of the R2 subunit of 
the GABA-B receptor 
Based on gene expression data, we attempted to evaluate the protein 
expression levels of the R2 subunit of the GABA-B receptor and the γ2 
subunit of the GABA-A receptor in the brain between WT and Sig1R− /−
Fig. 3. NE-100-induced acute seizure model. (A) Average behavioral scores for each group during the 60-min observation period. Data are expressed as the mean for 
each 1 min period. (B) The area under the curve (AUC0-60min) was calculated from the behavioral scoring curve. (C) Duration time of seizures for each animal and (D) 
latency time of NE-100-induced seizures. Data are expressed as the mean ± SEM (n = 9). *p < 0.05 Sig1R− /− mice vs WT mice (Mann-Whitney test). 
Fig. 4. Comparison of the duration of each observed seizure behavior after administration of NE-100 in WT and Sig1R− /− mice. The different behavioral categories 
include: trembling or wobbly gait (TR/W), tail lifting (Tail), clonic, tonic and clonic-tonic seizures while lying on the belly (C, T and C-T up, respectively), clonic, 
tonic and clonic-tonic seizures while lying on the side (C, T and C-T side, respectively), generalized seizures with wild jumping and running (G), and motionless or 
sleeping (ML/S). Data are expressed as the mean ± SEM (n = 9). *p < 0.05 and #p = 0.06 Sig1R− /− mice vs WT mice (Mann-Whitney test). 
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mice by using Western blot analysis. Sig1R− /− mice demonstrated 
significantly decreased expression of the GABA-B receptor R2 subtype 
compared to WT mice (Fig. 5A and B). The results showed no significant 
differences in the expression of the γ2 subunit of the GABA-A receptor 
between WT and Sig1R− /− animals (Fig. 5A and C). Although NE-100 
induced a significant downregulation of the expression of the γ2 subunit 
of the GABA-A receptor, no difference in protein levels was observed in 
WT mice (Supplementary Fig. 1A and Supplementary Fig. 1B) and 
Sig1R− /− mice (Supplementary Fig. 1C and Supplementary Fig. 1D) 
after administration of NE-100. In addition, NE-100 was not observed to 
bind directly to the GABA-A receptor in the [3H]muscimol binding assay 
(Supplementary Fig. 2). 
To test which brain regions have decreased expression of the GABA-B 
receptor in Sig1R− /− mice, immunohistochemical staining of both the 
R1 and R2 subunits of the GABA-B receptor was performed (Fig. 5D, E 
and I). Sig1R− /− mice demonstrated significantly increased staining of 
GABA-B R1 in the stratum oriens (Mann-Whitney U test: p = 0.0043) and 
stratum radiatum (Mann-Whitney U test: p = 0.0260) while reduced 
staining of GABA-B R2 was observed in the stratum oriens (Mann-Whit-
ney U test: p = 0.0108), stratum radiatum (Mann-Whitney U test: p =
0.0087) and stratum lacunosum-moleculare (Mann-Whitney U test: p =
0.0022) of the hippocampal Cornu Ammonis 1 (CA1) region (Fig. 5G). 
The most marked difference in the staining of the R2 subunit of the 
GABA-B receptor in Sig1R − /− mice was found in the habenula (Fig. 5I). 
The expression of the R2 subunit of the GABA-B receptor was signifi-
cantly decreased in the Sig1R − /− mice medial and lateral habenula 
(Mann-Whitney U test: p = 0.0022 and p = 0.0476, respectively; 
Fig. 5K). Immunofluorescence staining of the GABA-B R2 in the medial 
habenula confirmed DAB staining results (Mann-Whitney U test: p =
0.0022; Fig. 6A and B). By using co-labeling experiments the most sig-
nificant decrease of the R2 staining of the GABA-B receptor in Sig1R− /−
mice was found in the ventral part of the medial habenula (Fig. 6C and 
D) and was confirmed with confocal imaging (Fig. 6E). GABA-B R1 
staining in the habenula did not differ between WT and Sig1R− /− an-
imals (Fig. 5J and Fig. 6E). Administration of NE-100 did not change the 
GABA-B R2 protein levels in the hippocampus (Supplementary Table 2) 
and habenula (Supplementary Fig. 4A and 4B) of WT and Sig1R− /−
mice. We did not observe any significant difference in the staining of the 
γ2 subunit of the GABA-A receptor in the brain between WT and 
Sig1R− /− mice (Fig. 5E, H, I and L). 
3.5. NE-100 enhances electrically stimulated contractions of isolated vasa 
deferentia and inhibits KCl-induced maximal contractility 
The isolated vasa deferentia model has been used previously to test 
and describe the activity of Sig1R ligands. The activity of NE-100 on 
electrical field stimulation-induced contractions of isolated vasa defer-
entia of WT and Sig1R− /− mice was investigated. NE-100 dose-depen-
dently enhanced electrical current-induced contractions of the vasa 
deferentia of WT and Sig1R − /− mice (Fig. 7A). A two-way repeated 
measures ANOVA showed a significant interaction between concentra-
tion of NE-100 and genotype (F(3,33) = 43.9, p < 0.0001) and main ef-
fects of concentration of NE-100 (F(1, 16) = 98.6, p < 0.0001) and 
genotype (F(1,11) = 17.8, p = 0.0015; Fig. 7A). The contractions of vasa 
deferentia were significantly higher in WT than in Sig1R− /− mice after 
treatment with NE-100 at concentrations of 3 and 10 μM (two-way 
repeated measures ANOVA followed by Bonferroni test: p < 0.0001 and 
p < 0.0001, respectively; Fig. 7A). NE-100 significantly inhibited the 
response of vasa deferentia to KCl in both WT and Sig1R− /− animals 
(one-way ANOVA: F(3,22) = 56.7, p < 0.0001; Fig. 7B). Compared to WT 
mice, Sig1R− /− mice demonstrated decreased maximal contractility of 
vasa deferentia, which was measured by the addition of 100 mM KCl 
(one-way ANOVA followed by Tukey’s test: p = 0.0011; Fig. 7B). We 
examined the dose-dependent activity of barium chloride, a nonspecific 
inhibitor of inward-rectifier potassium channels, on the contractility of 
vasa deferentia isolated from WT and Sig1R− /− animals (Fig. 7C). 
Barium chloride dose-dependently enhanced electrical current-induced 
contractions of both genotype vasa deferentia (two-way repeated- 
measures ANOVA: F(5, 50) = 179.3, p < 0.0001 for concentration of 
barium chloride; Fig. 7C). The effect of barium chloride was significantly 
less pronounced on vasa deferentia isolated from Sig1R− /− mice (two- 
way repeated measures ANOVA: F(5, 50) = 10.1, p < 0.0001 for con-
centration of barium chloride and genotype interaction; Fig. 7C). 
4. Discussion 
This study demonstrates a reduced tonic seizure threshold of 
Sig1R− /− animals in PTZ and BIC-induced acute seizure models and 
decreased expression of the R2 subunit of the GABA-B receptor in the 
ventral part of the medial habenula and CA1 region of hippocampus 
compared to that of age-matched WT mice. NE-100-induced seizure 
severity was significantly less pronounced in Sig1R− /− mice. Sig1R- 
independent downregulation of gene expression of iNOS and GABA- 
Aγ2 in the brain was observed 75 min after the administration of NE- 
100. Sig1R− /− animals showed a reduced response to KCl, which 
resulted in decreased maximal contractility of vasa deferentia compared 
to WT animals. NE-100 inhibited KCl-induced depolarization of the vasa 
deferentia in both WT and Sig1R− /− mice. 
Since Sig1R− /− mice previously exhibited dysfunction of GABA-A 
receptor-mediated inhibition (Zhang et al., 2017), to compare the 
seizure threshold in WT and Sig1R− /− animals, we used PTZ and BIC, 
which both inhibit the GABA-A receptor and induce seizures in naïve 
animals (Galanopoulou and Moshé, 2014). Our results showed that 
Sig1R− /− mice are more vulnerable to PTZ- and BIC-induced tonic 
seizures. To date, direct protein-protein interactions of Sig1R with the 
GABA receptors have not been demonstrated. Previously, the analysis of 
RT-PCR samples from C57Bl/6 background mice showed that the levels 
of GABA-Aα4 and GABA-Aδ mRNA in brain samples from the basolateral 
amygdala did not differ significantly between Sig1R− /− and WT mice 
(Zhang et al., 2017). In addition, we did not find differences in GABA- 
Aα5, GABA-Aβ3 and GABA-Aγ2 mRNA levels in CD-1 background 
Sig1R− /− mouse brain samples. Western blotting results showed that 
the γ2 subunit of GABA-A receptor expression in brain samples was not 
altered in Sig1R− /− mice compared to WT animals. It was reported 
previously that the direct function of the GABA-A receptor in 
Table 1 
Gene expression.  





Sigmar1 Sig1R – 0.8 ± 0.2 – 
Pgrmc1 Sig2R 1.1 ± 0.6 1.0 ± 0.2 0.9 ± 0.1 
Grin1 NMDAR1 1.0 ± 0.3 0.9 ± 0.3 0.8 ± 0.2 
Drd1 D1R 0.8 ± 0.4 1.1 ± 0.8 1.0 ± 0.5 
Drd2 D2R 0.8 ± 0.5 1.0 ± 0.8 1.0 ± 0.6 
Nos2 iNOS 1.0 ± 0.5 0.5 ± 0.2 ↓* 0.5 ± 0.1 ↓* 
Gabra5 GABA-A α5 1.0 ± 0.8 1.1 ± 0.3 0.8 ± 0.2 
Gabrb3 GABA-A β3 1.1 ± 0.6 0.9 ± 0.2 0.8 ± 0.1 
Gabrg2 GABA-A γ2 0.9 ± 0.7 0.4 ± 0.4 ↓* 0.5 ± 0.3 ↓* 
Gabbr1 GABA-B R1 0.9 ± 0.1 0.9 ± 0.3 0.9 ± 0.2 
Gabbr2 GABA-B R2 0.6 ± 0.3 ↓ 1.3 ± 0.6 1.2 ± 0.3 
HSPA5 BiP 0.9 ± 0.2 1.1 ± 0.4 0.8 ± 0.4 
P2rx1 P2RX1 0.7 ± 0.5 0.7 ± 0.4 1.1 ± 0.3 
Ryr3 RyR3 0.9 ± 0.2 1.1 ± 0.6 0.7 ± 0.2 
Kcnj3 Kir3.1 0.8 ± 0.1 0.9 ± 0.4 1.0 ± 0.6 
Kcnj9 Kir3.3 0.7 ± 0.1 0.6 ± 0.3 ↓ 0.8 ± 0.3 
Aif1 Iba1 1.1 ± 0.4 1.3 ± 0.8 1.0 ± 0.3 
Cd68 CD68 1.2 ± 0.6 1.1 ± 0.1 0.8 ± 0.2 
The relative expression levels for each gene were calculated with the ΔΔCt 
method, normalized to the expression level of β-actin and compared to the 
expression levels of WT control mice. Data are expressed as the mean fold 
change ± SD. *p < 0.05 NE-100 vs respective genotype control (n = 5; Mann- 
Whitney U test). 
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Fig. 5. GABA-A and GABA-B receptor expression in WT and Sig1R− /− mouse brains. Western blot images (A) and calculated relative amounts of the R2 subunit of 
the GABA-B (B) and γ2 subunit of the GABA-A (C) receptors of WT vs Sig1R− /− control animals. Data are expressed as the mean ± SD (n = 5). *p < 0.05 Sig1R− /−
mice vs WT mice (Mann-Whitney U test). Overview of GABA-B R2 staining in WT (on the left) and Sig1R− /− (on the right) mouse brain hemispheres (D) with the 
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hippocampal pyramidal neurons of Sig1R− /− mice is not changed (Sha 
et al., 2013). Therefore, different seizure thresholds in PTZ- and BIC- 
induced seizure models could not be associated with different 
amounts or functions of the GABA-A receptor in CD-1 background WT 
and Sig1R− /− mice. 
In our study, we demonstrated significantly decreased expression of 
indicated areas used for analysis. Representative images of immunohistochemical staining in the hippocampus (E) and habenula (I). Measured optical density (OD) of 
the staining intensity of the GABA-B R1 in the hippocampus (F), and habenula (J), GABA-B R2 in the hippocampus (G) and habenula (K) and GABA-A γ2 in the 
hippocampus (H) and habenula (L). Data are expressed as the mean ± SD (n = 6). *p < 0.05 Sig1R− /− mice vs WT mice (Mann-Whitney U test). Cornu Ammonis 1 
(CA1), dentate gyrus (DG), stratum oriens (so), pyramidal layer (pl), stratum radiatum (sr), stratum lacunosum-moleculare (slm), molecular layer (mo), granule cell layer 
(gcl), polymorph layer (po), medial habenula (MHb) and lateral habenula (LHb). 
Fig. 5. (continued). 
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the R2 subunit of the GABA-B receptor in the habenula and hippocam-
pus of Sig1R− /− mouse brain tissue. We found significantly increased 
expression of R1 subunit of GABA-B receptors in the CA1 region of the 
hippocampus of Sig1R− /− mice. This could be considered as a 
compensatory mechanism in Sig1R− /− animals due to decreased 
expression of the R2 subunit of the GABA-B receptor in the structures of 
CA1. Altered GABA-B receptor function has been associated with a va-
riety of neurological and psychiatric disorders, including epilepsy, 
depression, anxiety, cognition, nociception and drug addiction 
(reviewed in Han et al., 2013; Felice et al., 2016; Terunuma, 2018), and 
Sig1R has been established as a molecular target to treat the above-
mentioned disorders (Maurice and Su, 2009; Vavers et al., 2019). In 
addition, it has been demonstrated that the medial habenula plays an 
important role in stress, depression, memory and addiction (Viswanath 
et al., 2014). Functional GABA-B receptors are heterodimers whose 
function depends on the dimerization of the GABA-B R1 and GABA-B R2 
subunits (reviewed in Bowery et al., 2002; Frangaj and Fan, 2018). It has 
been shown that mice lacking either the R1 or R2 subunit of the GABA-B 
receptor demonstrate altered anxiety and depression-related behavior 
(Mombereau et al., 2005), which is associated with behavioral changes 
found in C57Bl/6 background Sig1R− /− mice (Sabino et al., 2009; 
Chevallier et al., 2011; Couly et al., 2020). In addition, spontaneous 
seizures have been observed in GABA-B R2 subunit knockout mice 
(Mombereau et al., 2005). The medial habenula is divided into two 
subnuclei on the basis of cell type: cholinergic neurons are located in the 
ventral part of the medial habenula while Substance P-ergic neurons are 
located exclusively in the dorsal part of the medial habenula (Lee et al., 
2019). By using Substance P and ChAT as markers of the dorsal and 
ventral parts of the medial habenula, respectively, we demonstrated that 
the decrease of the R2 subunit of the GABA-B receptor in Sig1R− /− mice 
is present in the ventral part of the medial habenula. In the brain, the 
medial habenula contains one of the highest concentrations of GABA-B 
receptors, suggesting the presence of strong inhibitory inputs 
(Viswanath et al., 2014). Presynaptic GABA-B receptors are abundant in 
cholinergic neurons of the medial habenula and control not only the 
release of acetylcholine but also glutamate (Lee et al., 2019). The 
reduced expression of the GABA-B receptor R2 subunit and disturbed 
GABA-B receptor function may explain the neurobehavioral phenotype 
of Sig1R− /− mouse and higher susceptibility to seizures. 
GABA-B receptor agonists have been shown to diminish seizure ac-
tivity in mouse models of both generalized convulsive and focal seizures 
(Joshi et al., 2016). Activation of GABA-B receptors with R-baclofen 
dose-dependently attenuated PTZ-induced kindling in CD-1 mice, while 
inhibition of GABA-B receptor by antagonists CGP 35348 and CGP 
55845 resulted in more rapid development of kindling in the same 
model (De Sarro et al., 2000). It has been shown that activation of the 
GABA-B receptor in rat globus pallidus can reduce PTZ-induced tonic 
seizures (Chen et al., 2004). In patients with temporal lobe epilepsy 
significantly decreased number of GABA-B receptor binding sites were 
observed in the hippocampus (Furtinger et al., 2003). Taken together, 
these findings suggest that the reduced expression of the GABA-B re-
ceptor could explain why Sig1R− /− mice demonstrate a significantly 
increased susceptibility to PTZ- and BIC-induced tonic seizures. On the 
other hand, the GABA-B receptor agonist baclofen may possess a pro-
convulsant effect which is caused by a presynaptic GABA-B receptor- 
mediated inhibition of GABA release leading to disinhibition (Motalli 
et al., 1999; Han et al., 2013). Therefore, GABA-B receptor antagonists 
are thought to be promising for treating atypical absence seizures 
observed in Lennox-Gastaut syndrome (Han et al., 2013). In the medial 
habenula GABA-B receptors are known to mediate excitation through a 
unique signaling mechanism which comprises amplification of presyn-
aptic Ca2+ entry through Cav2.3 channels and potentiation of co-release 
of glutamate and acetylcholine to excite interpeduncular neurons 
(Zhang et al., 2016). Interestingly, fenfluramine, a positive allosteric 
modulator of Sig1R (Martin et al., 2020), has been shown to be clinically 
effective in reducing seizures in patients with Lennox-Gastaut syndrome 
Fig. 5. (continued). 
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Fig. 6. Immunofluorescence of the R2 subunit of GABA-B receptors in the medial habenula. (A) Comparison of GABA-B R2 expression in WT and Sig1R− /− mice by 
using immunofluorescence, (B) measured corrected total cell fluorescence (CTCF). Data are expressed as the mean ± SD (n = 6). *p < 0.05 Sig1R− /− mice vs WT 
E. Vavers et al.                                                                                                                                                                                                                                  
Neurobiology of Disease 150 (2021) 105244
12
mice (Mann-Whitney U test). (C) DAB and immunofluorescence staining of Substance P (a marker of the dorsal part of the medial habenula, red) and double im-
munostaining with R2 subunit of GABA-B receptors (green). Red line demonstrates dorsal part and green line demonstrates ventral part of the medial habenula. (D) 
Combined DAB and immunofluorescence staining of ChAT (a marker of the ventral part of the medial habenula) and GABA-B R2 (green), respectively. (E) A 
representative confocal image demonstrating colocalization of R1 subunit (green) and R2 subunit (red) of the GABA-B receptor in the ventral part of the medial 
habenula of WT and Sig1R− /− mice. 
Fig. 6. (continued). 
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(Lagae et al., 2018), in which the most common seizure type is tonic 
seizures (Intusoma et al., 2013). Our data showed that Sig1R− /− mice 
demonstrate a significantly reduced threshold for tonic seizures, which 
suggests the possible role played by the Sig1R-GABA-B interaction in 
seizures in which the tonic component is the most common. Since GABA- 
B receptor-mediated mechanisms can be pro- and anti-convulsive (Joshi 
et al., 2016), this finding could explain the phenomena described for 
several Sig1R agonists and antagonists, which could also be pro- and 
anti-convulsive. 
In the NE-100-induced seizure model, significantly reduced seizure 
severity was observed in Sig1R− /− animals and was presented as a 
lower seizure score, shorter duration and increased latency time of sei-
zures compared to WT mice. These observations strengthen the pivotal 
role played by Sig1R in the control of seizures. However, the Sig1R 
antagonist NE-100 induced seizures not only in WT but also in Sig1R− / 
− animals. The mechanism of how NE-100 induces seizures is not 
known. We found that NE-100-induced seizures resulted in Sig1R- 
independent downregulation of iNOS and GABA-Aγ2 receptor subunit 
genes in both WT and Sig1R− /− animals, despite the different seizure 
severity observed in these animals after administration of NE-100. 
Recently, it was demonstrated that NE-100 can dose-dependently 
inhibit the exocytotic release of GABA and glutamate in synaptosomes 
isolated from rat brain (Pozdnyakova et al., 2020). In addition, bidi-
rectional activity of NE-100 was observed on GABA uptake in rat brain 
synaptosomes (Pozdnyakova et al., 2020). Therefore, it seems that NE- 
100 dose-dependently disturbs the balance of excitation and inhibi-
tion. Since Sig1R− /− mice show decreased expression of the GABA-B R2 
subunit and significantly lower seizure severity in the NE-100-induced 
seizure model, it is possible that the NE-100-induced seizure severity 
could be modulated through the level of the GABA-B R2 subunit and the 
activity of GABA-B receptor. 
We also found that Sig1R− /− mice showed a decreased response to 
KCl and subsequently weaker maximal contraction in an isolated vasa 
deferentia model compared to WT animals. Recently, it was confirmed 
that Sig1R behaves as an atypical auxiliary subunit to modulate potas-
sium channel function (Abraham et al., 2019). Therefore, the difference 
in the contractile response between WT and Sig1R− /− mice could be 
due to the different functions of potassium channels. It is known that 
activation of the postsynaptic GABA-B receptor activates inward- 
rectifier potassium channels (Bowery et al., 2002). The inhibitory ac-
tion of Sig1R on the inward-rectifier potassium channel Kir2.1 has been 
previously demonstrated (Wong et al., 2016). Interestingly, the inhibi-
tion of inward-rectifier potassium channels by barium chloride results in 
an increase in contractions of isolated vasa deferentia (Diaz-Toledo and 
Jurkiewicz, 1991). In our study, the effect of barium chloride was less 
pronounced on the vasa deferentia isolated from Sig1R− /− mice, which 
confirms the role of inward-rectifier potassium channel function in this 
(caption on next column) 
Fig. 7. Isolated vasa deferentia model. (A) NE-100-enhanced electrical current- 
induced contractions of vasa deferentia. Data are shown as the mean ± SD (n = 6 
WT, n = 7 Sig1R− /− mice). *p < 0.05 dose-dependent effect of NE-100 vs 
baseline of WT mice, $p < 0.05 dose-dependent effect of NE-100 vs baseline of 
Sig1R− /− mice (two-way repeated measures ANOVA followed by Dunnett’s 
test for comparison with baseline within each group); #p < 0.05 WT vs Sig1R− / 
− (two-way repeated measures ANOVA followed by Bonferroni test for com-
parison of NE-100 effect between genotypes). (B) The effect of 10 μM NE-100 
on KCl-induced maximal contractility. Data are shown as the mean ± SD (n 
= 6 WT, n = 7 Sig1R− /− mice). *p < 0.05 vs WT control; #p < 0.05 vs Sig1R− / 
− control (one-way ANOVA followed by Tukey’s test). (C) The effect of barium 
chloride, a nonspecific inhibitor of inward-rectifier potassium channels, on the 
contractility of vasa deferentia. Data are shown as the mean ± SD (n = 6 WT, n 
= 6 Sig1R− /− mice). *p < 0.05 dose-dependent effect of barium chloride vs 
baseline of WT mice, $p < 0.05 dose-dependent effect of barium chloride vs 
baseline of Sig1R− /− mice (two-way repeated measures ANOVA followed by 
Dunnett’s test for comparison with baseline within each group); #p < 0.05 WT 
vs Sig1R− /− (two-way repeated measures ANOVA followed by Bonferroni test 
for comparison of barium chloride effect between genotypes). 
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model. Similar to barium chloride, administration of NE-100 in an iso-
lated vasa deferentia model resulted in a significant dose-dependent 
enhancement of electrical current-induced contraction amplitude in 
WT mice, while there was a significantly reduced effect of NE-100 on 
vasa deferentia isolated from Sig1R− /− mice. It should be noted that 
Sig1R agonists PRE-084, (+)-pentazocine and antagonists BD-1047 and 
NE-100 were shown to similarly inhibit the KCl-induced increase in 
[Ca2+]i in both WT and Sig1R− /− mouse brain synaptosomes and thus 
demonstrated Sig1R-independent effects of these ligands on KCl- 
induced depolarization (González et al., 2012). In keeping with previ-
ous findings, we also found a Sig1R-independent inhibitory effect of NE- 
100 on KCl-induced maximal contractility of WT and Sig1R− /− mouse 
vasa deferentia, which could be due to Sig1R-independent activity of NE- 
100 on inward-rectifier potassium channels. 
5. Conclusions 
Our results strongly demonstrate the reduced expression of the R2 
subunit of the GABA-B receptor in the brain due to the genetic inacti-
vation of Sig1R and supports the significance of Sig1R and GABA-B re-
ceptor cooperation in the modulation of the seizure threshold. Sig1R is a 
significant molecular target for seizure modulation and warrants further 
investigation for the development of novel anti-seizure drugs. 
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